145 related articles for article (PubMed ID: 21149806)
1. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.
Kim SH; Kim W; Park MS; Sohn EH; Li XF; Kim HJ
Arch Neurol; 2011 Apr; 68(4):473-9. PubMed ID: 21149806
[TBL] [Abstract][Full Text] [Related]
2. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
Weinstock-Guttman B; Ramanathan M; Lincoff N; Napoli SQ; Sharma J; Feichter J; Bakshi R
Arch Neurol; 2006 Jul; 63(7):957-63. PubMed ID: 16831964
[TBL] [Abstract][Full Text] [Related]
3. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
[TBL] [Abstract][Full Text] [Related]
4. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
[TBL] [Abstract][Full Text] [Related]
5. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
[TBL] [Abstract][Full Text] [Related]
6. Interferon-beta(1b) treatment in neuromyelitis optica.
Tanaka M; Tanaka K; Komori M
Eur Neurol; 2009; 62(3):167-70. PubMed ID: 19590215
[TBL] [Abstract][Full Text] [Related]
7. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.
Papeix C; Vidal JS; de Seze J; Pierrot-Deseilligny C; Tourbah A; Stankoff B; Lebrun C; Moreau T; Vermersch P; Fontaine B; Lyon-Caen O; Gout O
Mult Scler; 2007 Mar; 13(2):256-9. PubMed ID: 17439893
[TBL] [Abstract][Full Text] [Related]
9. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ
Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309
[TBL] [Abstract][Full Text] [Related]
10. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
[TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica.
Weinstock-Guttman B; Miller C; Yeh E; Stosic M; Umhauer M; Batra N; Munschauer F; Zivadinov R; Ramanathan M
Mult Scler; 2008 Sep; 14(8):1061-7. PubMed ID: 18573816
[TBL] [Abstract][Full Text] [Related]
12. NMO-IgG predicts the outcome of recurrent optic neuritis.
Matiello M; Lennon VA; Jacob A; Pittock SJ; Lucchinetti CF; Wingerchuk DM; Weinshenker BG
Neurology; 2008 Jun; 70(23):2197-200. PubMed ID: 18434643
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
Enriquez CAG; Espiritu AI; Pasco PMD
J Neuroimmunol; 2019 Jul; 332():126-134. PubMed ID: 31005713
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
Pellkofer HL; Krumbholz M; Berthele A; Hemmer B; Gerdes LA; Havla J; Bittner R; Canis M; Meinl E; Hohlfeld R; Kuempfel T
Neurology; 2011 Apr; 76(15):1310-5. PubMed ID: 21482945
[TBL] [Abstract][Full Text] [Related]
15. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
Miyamoto K; Kusunoki S
Ther Apher Dial; 2009 Dec; 13(6):505-8. PubMed ID: 19954473
[TBL] [Abstract][Full Text] [Related]
16. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
Pellkofer HL; Suessmair C; Schulze A; Hohlfeld R; Kuempfel T
Mult Scler; 2009 Aug; 15(8):1006-8. PubMed ID: 19667025
[TBL] [Abstract][Full Text] [Related]
17. Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations.
Hamnik SE; Hacein-Bey L; Biller J; Gruener G; Jay W
Semin Ophthalmol; 2008; 23(3):191-200. PubMed ID: 18432545
[TBL] [Abstract][Full Text] [Related]
18. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica.
Mok CC; To CH; Mak A; Poon WL
J Rheumatol; 2008 Jan; 35(1):172-4. PubMed ID: 18176991
[TBL] [Abstract][Full Text] [Related]
19. Impact of rituximab on relapse rate and disability in neuromyelitis optica.
Bedi GS; Brown AD; Delgado SR; Usmani N; Lam BL; Sheremata WA
Mult Scler; 2011 Oct; 17(10):1225-30. PubMed ID: 21622594
[TBL] [Abstract][Full Text] [Related]
20. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder.
Bonnan M; Valentino R; Olindo S; Mehdaoui H; Smadja D; Cabre P
Mult Scler; 2009 Apr; 15(4):487-92. PubMed ID: 19324982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
